On­coSec signs on Dana-Far­ber as CAR-T part­ner; Do­va racks up an­oth­er Doptelet ap­proval

Dana-Far­ber is lend­ing a hand to lit­tle On­coSec’s nascent ef­fort to de­vel­op CAR-T ther­a­pies for sol­id tu­mor can­cers. The San Diego biotech has worked out an ex­clu­sive li­cens­ing deal with Wayne Maras­co — an ex­pert in an­ti­body en­gi­neer­ing — to ap­ply his method of link­ing two sin­gle-chain vari­able frag­ment (scFv) in a bis­pe­cif­ic CAR-T such that the T cells are on­ly ac­ti­vat­ed when both tar­gets are en­gaged, there­by lim­it­ing off-tu­mor tox­i­c­i­ty. On­coSec’s fi­nan­cial con­tri­bu­tion in the re­search, which in­volves test­ing the ex­per­i­men­tal treat­ment so­lo and in com­bi­na­tion with Ta­vo in triple-neg­a­tive breast can­cer, will be “mod­est” and spread over sev­er­al years, CEO Daniel O’Con­nor said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.